Quarterly report [Sections 13 or 15(d)]

Consolidated Balance Sheets

v3.26.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Assets    
Cash and cash equivalents $ 900 $ 1,303
Receivable for cash held back from the asset sale 1,248
Receivable, related party 15
Prepaid expenses and other current assets 759 676
Current assets held for sale 26,930
Total Current assets 2,922 28,909
Investment in DNA X LLC under equity method 1,242
Identifiable intangible assets 1,379
Deferred tax assets 1,441
Other assets 216 274
Non-current assets held for sale 12,032
Total assets 4,517 43,898
Liabilities and stockholders’ deficit    
Accounts payable 683 4,030
Accrued liabilities 960 704
Derivative liability 797 171
Income tax payable 309 2,598
Current liabilities held for sale 38,057
Total current liabilities 5,149 50,625
Deferred tax liability 600
Total liabilities 5,749 50,625
Commitments and contingencies (Note 10)
Redeemable common stock; $0.001 par value; 223,201 shares issued and outstanding; redemption value $1,228 as of December 31, 2025 (Note 7) 1,228
Stockholders’ deficit    
Common stock, $0.001 par value per share; 1,000,000,000 shares authorized: and 1,488,268 and 1,265,067 shares issued and outstanding at June 30, 2026 and December 31, 2025 respectively [1] 1 1
Preferred stock, $0.001 par value per share, 5,000,000 shares authorized: and no shares issued and outstanding at June 30, 2026 and December 31, 2025
Additional paid-in capital [1] 297,674 296,309
Accumulated deficit (298,907) (304,265)
Total stockholders’ deficit (1,232) (7,955)
Total liabilities, redeemable common stock, and stockholders’ deficit 4,517 43,898
Related Party [Member]    
Liabilities and stockholders’ deficit    
Promissory notes, net 2,400 1,035
Nonrelated Party [Member]    
Liabilities and stockholders’ deficit    
Promissory notes, net $ 4,030
[1] Adjusted retroactively to reflect the 1-for-18 reverse stock split that became effective on October 28, 2025, see Note 1.